KR20030019587A - 바이러스 감염의 치료에 있어서 ｉｌ-8 수용체 길항제의용도 - Google Patents

바이러스 감염의 치료에 있어서 ｉｌ-8 수용체 길항제의용도 Download PDF

Info

Publication number
KR20030019587A
KR20030019587A KR10-2003-7000717A KR20037000717A KR20030019587A KR 20030019587 A KR20030019587 A KR 20030019587A KR 20037000717 A KR20037000717 A KR 20037000717A KR 20030019587 A KR20030019587 A KR 20030019587A
Authority
KR
South Korea
Prior art keywords
respiratory
viral infection
therapeutic agent
human
infection
Prior art date
Application number
KR10-2003-7000717A
Other languages
English (en)
Korean (ko)
Inventor
수잔 비. 딜론
루쓰 탈싱거
Original Assignee
스미스클라인 비참 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스미스클라인 비참 코포레이션 filed Critical 스미스클라인 비참 코포레이션
Publication of KR20030019587A publication Critical patent/KR20030019587A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR10-2003-7000717A 2000-07-18 2001-07-16 바이러스 감염의 치료에 있어서 ｉｌ-8 수용체 길항제의용도 KR20030019587A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21905300P 2000-07-18 2000-07-18
US60/219,053 2000-07-18
PCT/US2001/022328 WO2002005814A1 (en) 2000-07-18 2001-07-16 Use of il-8 receptor antagonists in the treatment of virus infections

Publications (1)

Publication Number Publication Date
KR20030019587A true KR20030019587A (ko) 2003-03-06

Family

ID=22817645

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7000717A KR20030019587A (ko) 2000-07-18 2001-07-16 바이러스 감염의 치료에 있어서 ｉｌ-8 수용체 길항제의용도

Country Status (17)

Country Link
EP (1) EP1307190A4 (ja)
JP (1) JP2004509852A (ja)
KR (1) KR20030019587A (ja)
CN (1) CN1449285A (ja)
AR (1) AR033830A1 (ja)
AU (1) AU2001273497A1 (ja)
BR (1) BR0112603A (ja)
CA (1) CA2418162A1 (ja)
CZ (1) CZ2003132A3 (ja)
HU (1) HUP0300754A3 (ja)
IL (1) IL153921A0 (ja)
MX (1) MXPA03000500A (ja)
NO (1) NO20030201L (ja)
NZ (1) NZ523659A (ja)
PL (1) PL365886A1 (ja)
WO (1) WO2002005814A1 (ja)
ZA (1) ZA200300474B (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001561A (es) * 2004-08-04 2007-04-16 Schering Corp Formulacion farmaceutica que comprende pleconaril para tratamiento de enfermedades de vias aereas.
CN107072976A (zh) * 2014-05-12 2017-08-18 葛兰素史克知识产权第二有限公司 用于治疗传染性疾病的包含Danirixin的药物组合物
EP4008325A1 (en) * 2020-12-02 2022-06-08 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
WO2021191305A1 (en) * 2020-03-26 2021-09-30 Dompe' Farmaceutici Spa Cxcl8 inhibitors for use in the treatment of covid-19
EP3884932A1 (en) * 2020-03-26 2021-09-29 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
AU3539795A (en) * 1994-08-25 1996-03-14 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9802937D0 (sv) * 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds

Also Published As

Publication number Publication date
CZ2003132A3 (cs) 2003-09-17
CN1449285A (zh) 2003-10-15
EP1307190A1 (en) 2003-05-07
CA2418162A1 (en) 2002-01-24
HUP0300754A3 (en) 2009-03-02
BR0112603A (pt) 2004-08-24
JP2004509852A (ja) 2004-04-02
AR033830A1 (es) 2004-01-07
NZ523659A (en) 2006-01-27
NO20030201D0 (no) 2003-01-15
WO2002005814A1 (en) 2002-01-24
EP1307190A4 (en) 2007-08-22
AU2001273497A1 (en) 2002-01-30
HUP0300754A2 (hu) 2003-08-28
ZA200300474B (en) 2004-08-17
PL365886A1 (en) 2005-01-10
IL153921A0 (en) 2003-07-31
NO20030201L (no) 2003-03-17
MXPA03000500A (es) 2003-06-24

Similar Documents

Publication Publication Date Title
AU716821B2 (en) Method to improve the biological and antiviral activity of protease inhibitors
Mehla et al. Programming of neurotoxic cofactor CXCL-10 in HIV-1-associated dementia: abrogation of CXCL-10-induced neuro-glial toxicity in vitro by PKC activator
KR20040084913A (ko) 염증 및 ａｉｄｓ-관련된 신경계 장애의 치료 방법 및조성물
JP3306830B2 (ja) レトロウイルスインテグラーゼの阻害剤
US6894021B2 (en) Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
Yoon et al. Rhinovirus regulation of IL-1 receptor antagonist in vivo and in vitro: a potential mechanism of symptom resolution
WO2021214299A1 (en) Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
Bergamini et al. Macrophage colony-stimulating factor enhances the susceptibility of macrophages to infection by human immunodeficiency virus and reduces the activity of compounds that inhibit virus binding
KR20030019587A (ko) 바이러스 감염의 치료에 있어서 ｉｌ-8 수용체 길항제의용도
US20040038854A1 (en) Use of il-8 receptor antagonists in the treatment of virus infections
Song et al. Human interleukin‐6 induces human herpesvirus‐8 replication in a body cavity‐based lymphoma cell line
US20040022762A1 (en) Use of il-8 protein modulators in the treatment of viral infections
JP2004083576A (ja) Ｈｉｖ感受性株に対して活性をもち、ヌクレオシド系ならびに非ヌクレオシド系の逆転写酵素阻害剤、およびプロテアーゼ阻害剤に対し抵抗性のｈｉｖ株に対して活性をもつ抗レトロウイルス治療薬を得るための、クロロキン、ヒドロキシクロロキン、および４アミノ−キノリン酸誘導体の使用
TW200418812A (en) IL-8 receptor antagonists
Benelli et al. Distinct chemotactic and angiogenic activities of peptides derived from Kaposi's sarcoma virus encoded chemokines.
EP0425109B1 (en) 3-Substituted-2-oxindole derivatives as inhibitors of interleukin-1 biosynthesis
JP7069120B2 (ja) エボラ（ｅｂｏｌａ）及びマールブルク（ｍａｒｂｕｒｇ）病を治療するためのｔｌｒ４拮抗薬としてのエリトランの使用方法
Pedersen et al. Effects of Chloroquine, Mefloquine and Quinine on Natural Killer Cell Activity in vitro: An Analysis of the Inhibitory Mechanism
WO2006041838A2 (en) Heparinoid compositions for treatment and prevention of dementia
Kalovidouris Dysfunction of the sarcoplasmic reticulum in polymyositis
CA2142831A1 (en) Treatment of human viral infections
KR101875997B1 (ko) 엔-메탄노카르바티미딘을 이용한 대상포진의 치료방법
US20130035357A1 (en) Compositions and Methods for Preventing Joint Destruction in Osteoarthritis
US8067430B1 (en) Anti-HIV activity of the opioid antagonist naloxone

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid